Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
| Autor: | Fernando Rivera, Javier Sastre, Pilar Bretes Garcia, Ferran Pérez-Alcántara, Joana Gostkorzewicz, Alfredo Carrato, Patricia Benedit, Rafael López, Teresa Macarulla |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
medicine.medical_specialty endocrine system diseases Paclitaxel Cost-Benefit Analysis Deoxycytidine chemistry.chemical_compound Albumin bound paclitaxel Internal medicine Albumins Metastatic pancreatic cancer Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Neoplasm Metastasis health care economics and organizations Nab-paclitaxel Cost–utility analysis business.industry Health Policy Cancer General Medicine medicine.disease Gemcitabine Markov Chains Quality-adjusted life year Pancreatic Neoplasms Models Economic chemistry Spain Quality-Adjusted Life Years business medicine.drug |
| Zdroj: | Expert review of pharmacoeconomicsoutcomes research. 15(4) |
| ISSN: | 1744-8379 |
| Popis: | The PANCOSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy data were obtained from the MPACT study and were modeled to a lifetime horizon using a Markov model. The analysis was performed from the payer's perspective. Use of resources and key assumptions of the analysis were validated by a panel of oncologists. The addition of nab-paclitaxel to GEM showed higher effectiveness results (0.156 additional quality adjusted life years) at a higher cost (€6,477), resulting in a cost per quality-adjusted life years gained of €41,519. The combination of nab-paclitaxel and GEM has been shown to be an effective and well-tolerated option for the treatment of metastatic pancreatic cancer and, in addition to becoming the new standard of care, could also be considered a cost-effective option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|